Improving care quality by engaging patients in shared decision making
By Randy Burkholder | March 22, 2018
With the rapid movement towards value-based payment and delivery in health care, it is critical not to leave one of the key players behind: the patient.
Read More
Phased-in approach offers best hope for FDA’s proposed quality metrics program
By Camille Jackson | April 7, 2016
In July 2015, the U.S. Food and Drug Administration (FDA) issued draft guidance for industry requiring manufacturers to provide certain manufacturing data on an annual basis. The FDA’s Center for...
Read More
Proposed quality metrics program raises operability questions
By Guest Contributor | March 25, 2016
Previously in this blog series, we’ve discussed PhRMA’s main recommendation for a phased-in approach to the U.S. Food and Drug Administration’s (FDA) proposed quality metrics program, as well as...
Read More
Transparency and confidentiality in FDA’s proposed quality metrics proposal is key
By Sarah Spurgeon | March 15, 2016
In our last post on this topic, we discussed PhRMA member companies’ commitment to quality and introduced you to the U.S. Food and Drug Administration’s (FDA) proposed mandatory quality metrics...
Read More
The biopharmaceutical industry’s commitment to quality
By Camille Jackson | February 11, 2016
America’s innovative biopharmaceutical companies are leaders in innovation and quality—not just in research and development, but also in manufacturing technology. PhRMA’s member companies...
Read More
Medicare Monday (100)
340B Spotlight (42)
Cost & Consequence (0)
